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It has been demonstrated that several niche factors allow adult and developing human and 1 6 5 murine intestinal epithelium to be cultured ex vivo as organoids (Capeling et al., 2019;  1 6 6 Finkbeiner et al., 2015; Fordham et al., 2013; Hill et al., 2017; Kraiczy et al., 2017; Sato et al., in vitro (Sato et al., 2009 (Sato et al., , 2011 . Efforts have been made to determine more physiological niche 1 7 0 factors for in vitro culture systems based on observed in vivo niche cues (Fujii et al., 2018) , 1 7 1 however these attempts at characterization have yet to fully leverage new high resolution 1 7 2 technologies such as scRNA-seq. To identify putative niche factors we first determined which 1 7 3 cells within the human fetal intestine expressed various known niche factors. We then identified 1 7 4 the cellular origin of each niche factor in silico with scRNA-seq data, and validated these 1 7 5 findings spatially in tissue sections using FISH/IF (Figure 2 Figure 2A , Figure S3 ), and expression of additional WNT and RSPO ligands was not detected. the epithelium, consistent with scRNA-seq data ( Figure 2B , Figure S3 ).
The TGFβ-family inhibitors NOG and CHRD appeared at low levels with NOG slightly enriched 1 9 8
( Figure 2C -D), a finding that was supported using co-FISH/IF and showed EGF is robustly 1 9 9 expressed only in the villus epithelium ( Figure 2E , Figure S2B ), several cell diameters above the 2 0 0 MK67+ crypt region ( Figure S2D ). 
1 4
Based on the expression pattern of NRG1, we hypothesized that it may act as an ERBB niche 2 1 5 signaling cue and may be physiologically relevant in vitro based on its localization and proximity 2 1 6
to ISCs within the developing intestine in vivo. To interrogate the effects of NRG1 and EGF on 2 1 7 the intestinal epithelium, we split human fetal duodenum derived epithelium-only intestinal 2 1 8 enteroids in culture using standard growth conditions (WNT3A/RSPO3/NOG plus EGF, see 2 1 9
Methods) into two groups. One group of enteroids was cultured in standard media with EGF 2 2 0 (100ng/mL), the other was grown without EGF and was instead supplemented with NRG1 2 2 1 (100ng/mL)( Figure 3A ). Following growth for 5 days in EGF or NRG1, enteroids did not appear 2 2 2 phenotypically different ( Figure 3A ), but each group was subjected to scRNA-seq to investigate To functionally evaluate the observation that proliferation was reduced in NRG1 treated 2 3 1 enteroids, we bulk passaged enteroids by fragmentation with a 30-gauge needle (see Methods) 2 3 2 and then allowed them to expand for 3 days in standard (EGF 100ng/mL) growth conditions. We 
4 4
The previous experiment was conducted with enteroids that had been established and 2 4 5 expanded in long-term culture with EGF, and the experimental data ( Figure 3) suggested that 2 4 6 these cultures were highly dependent on EGF. To determine the effects of different EGF-family 2 4 7 members on establishment and long-term growth of enteroids, we cultured freshly isolated 2 4 8 epithelium with EGF, NRG1 or a combination of EGF and NRG1 ( Figure 4A ). We used these 2 4 9 cultures to carry out imaging, quantitative enteroid forming assays and scRNA-seq ( Figure 4A ).
5 0
Isolated intestinal crypts were placed in Matrigel with culture medium containing no EGF/NRG1 2 5 1 (control), or containing NRG1 (100 ng/ml) plus increments of EGF (1-100ng/ml). Enteroids were 2 5 2 successfully established from intestinal crypts under all conditions ( Figure 4B ). We noted that 
6 3
All groups included 100ng/mL NRG1, and groups with 0 and 10ng/mL of EGF led to a ~1% 2 6 4 enteroid forming efficiency, whereas the 100ng/mL EGF group had ~0.5% enteroid forming 2 6 5 efficiency and the 1ng/mL EGF condition led to a ~5.6% enteroid forming efficiency ( Figure 4D ').
2 6 6 2 6 7
Given the morphological differences between cultures grown in NRG1 with no/low EGF and 2 6 8 high EGF, we wanted to interrogate the molecular differences between the groups. We 2 6 9 therefore generated scRNA-seq data for each group, and sequenced 3,448 cells grown in 2 7 0 0ng/mL EGF, 3,405 cells grown in 1ng/mL EGF, 1,932 cells grown in 10ng/mL EGF and 1,884 2 7 1 cells grown in 100ng/mL EGF. tSNE dimensional reduction suggested that enteroids grown in 2 7 2 low EGF (0, 1 ng/mL) clustered together, whereas enteroids grown in higher EGF (10, 2 7 3 100ng/mL) clustered together ( Figure 4E ). We further examined individual genes expressed in ( Figure 4H ). These data supported the notion that enteroids cultured under conditions with 2 9 0 NRG1 (100ng/mL) and low EGF (0-1ng/mL) possessed a higher proportion of enteroendocrine 2 9 1 cells (EEC), enterocytes and stem cells, but had fewer secretory cells compared to enteroids 2 9 2 grown in high EGF conditions.
9 3
Taken together, our data demonstrates that EGF strongly promotes proliferation in enteroids 2 9 4 generated from the developing human intestine, but that at high doses (10-100ng/mL), induces 2 9 5
reduced cellular diversity, with the majority of cells tending to skew towards the transcriptional 2 9 6
signature of secretory cells, including genes that are normally associated with gastric secretory 2 9 7
cells. In contrast, enteroids grown in NRG1 with low EGF have enhanced cellular diversity. and onward is maintained into adulthood (i.e. crypt-villus axis, muscle layers) it is possible that 3 1 7
there are dramatic differences across species and regions of the gut for the major niche cells.
1 8
In the current work, we identify a subepithelial cell that lines the entire crypt-villus axis, marked 
4 7
Taken together, our data reveals that the human fetal intestinal stem cell niche is composed of 3 4 8 multiple cellular sources, and highlights a unique role for different ligands from the EGF family.
4 9
The resources we provide here lay the groundwork to further interrogate cellular relationships in 3 5 0 the human fetal intestine, provide an important benchmark for in vitro experiments, and will 3 5 1 inform additional methods to generate more robust and physiologic culture conditions. 10ºC), and washed twice by suspension in 2 mL of HBSS + 1% BSA, followed by centrifugation.
3 0
Cells were counted using a hemocytometer, then spun down and resuspended to reach a antibodies and DAPI (1 µg/ml) were added and slides were incubated at room temperature for 1 4 6 8
hour. Excess secondary antibodies were rinsed off through a series of PBS washes, and slides 4 6 9
were mounted in ProLong Gold (TermoFisher, P36930). A list of antibodies and concentrations 4 7 0 can be found in the Key Resources Table. All imaging was done using a NIKON A1 confocal 4 7 1 and images were assembled using Photoshop CC. Z-stack series were captured and compiled 4 7 2
into maximum intensity projections using NIS-Elements (Nikon). Imaging parameters were kept 4 7 3 consistent for all images within the same experiment and any post-imaging manipulations were 4 7 4
performed equally on all images from a single experiment. Single-cell in silico analysis 4 7 7
All in silico analyses downstream of gene quantification was done using Scanpy with the 10x 4 7 8
Cellranger derived gene by cell matrices (Wolf et al., 2018) . All samples were filtered to remove 4 7 9 cells with less than 1000 or greater than 9000 genes, and less than 3500 or greater than 25000 4 8 0 counts per cell. Raw read counts per gene were scaled and log normalized prior to analysis.
8 1
Fetal tissue samples were batch corrected using BBKNN prior to dimensional reduction by 4 8 2 principal component calculation and UMAP (McInnes et al., 2018; Polański et al., 2019) . Genes 
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